CoMind’s latest $102.5 million funding round marks a major step forward for European health innovation. The London-based company is developing a non-invasive device that could make brain monitoring as routine as measuring blood pressure. Its success reflects the growing investor appetite Kylla observes for breakthrough medtech ventures that combine science, technology, and strong commercial potential.
London-based health-technology company CoMind has secured $102.5 million in funding to advance its pioneering non-invasive brain-monitoring device towards market launch in 2027. The new round, led by venture capital firm Plural, will support clinical validation and regulatory approval processes in the United States.
At Kylla, we closely follow and engage with the fast-growing European medtech and digital-health sectors. CoMind’s successful capital raise reflects the strong investor appetite we have seen among our international partners for innovative, AI-driven medical technologies that improve patient outcomes and healthcare efficiency.
Founded in 2018 by James Dacombe, CoMind is developing a medical device that can measure blood flow and pressure in the brain without surgery. Using low-powered infrared lasers and advanced data processing, the system can monitor cerebral blood flow, intracranial pressure, and autoregulation—vital metrics in cases of trauma, stroke, or cardiac surgery. The technology aims to make neurological monitoring as routine as measuring blood pressure.
The company has already conducted successful clinical trials in Barcelona and London, publishing research that demonstrates the safety and accuracy of its system. It is now preparing for a pivotal third clinical study in the United States as part of its submission to the Food and Drug Administration.
Taavet Hinrikus, co-founder of Wise and partner at Plural, praised Dacombe’s unconventional approach to innovation, drawing parallels with other transformative entrepreneurs who entered new industries with fresh perspectives. The investment marks a strong vote of confidence in both the science and scalability of CoMind’s technology.
Kylla remains committed to fostering relationships across the global health-innovation ecosystem and supporting visionary founders on their journey from early-stage funding to international expansion. The CoMind case exemplifies how patient-focused innovation, backed by strategic investors, can redefine entire segments of the healthcare market.
Investment Analyst
Kylla Corporate Transactions
